Kymriah (tisagenlecleucel, formerly CTL019) receives positive CHMP opinion for the treatment of two aggressive blood cancers, marking important milestone for patients in Europe
London, UK – 29 June 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the Committee for Medicinal Products…